Vertex Transferred Drug and study Sponsorship to Merck S

Project: Research project

Description

Vertex Transferred Drug and study Sponsorship to Merck Sept 2017 An Open-Label, First-in-Human Study of the Safety, Tolerability &Pharmacokinetics of VX-970 in Combination With Cytotoxic Chemotherapy in Subjects With Advanced Solid Tumors: Part C3 (SCLC)
StatusActive
Effective start/end date7/15/166/30/20

Funding

  • Vertex Pharmaceuticals Incorporated

Fingerprint

Pharmacokinetics
Safety
Drug Therapy
Pharmaceutical Preparations
Neoplasms
VX-970